Risky medication and contrast media-induced nephropathy in patients with diabetes and hypertension

Česká verzia

Authors: D. Krusová; K. Ševela; D. Králová; P. Žák; V. Olšovská
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2006; 52(11): 1014-1020
Category: Original Contributions

Summary

Contrast media-induced nephropathy (CMIN) is accompanied by high morbidity, lengthy hospitalization, and a higher mortality rate. In proportion to the rising number of diagnostic and interventional radiological procedures, the prevalence of this complication is also rising The study briefly tackles the currently known pathophysiological mechanisms that lead to CMIN and deals with various risk factors which increase the probability of development of contrast nephropathy. Among these factors are, in the first place, diabetes mellitus, a pre-existing renal illness and hypertension. In addition, the risk of developing CMIN significantly increases in patients on risky medication. In our study, this medication was a combination of ACEinhibitors (ACEI) and furosemide. Even though none of the patients met the criteria defined for CMIN, radiocontrast examination showed a significant statistical decline in glomerular filtration (GFR) and a rise in proteinuria (PU) in the sub-group which used this combination of medication. The risk level of this medication especially in patients with pre-existing nephropathy is also underlined by the suggested dependency of the relative rise in the serum levels of creatinine in terms of its input value. It is necessary, as early as the radiocontrast examination is being done, to bare in mind the possibility of CMIN occurring and avoid it also through the modification of the risk factors which can be influenced, e.g. elimination of risky medication and in indicated cases, taking preventive measures.

Key words:
nephropathy – contrast media-induced nephropathy – risk factors – preventive measures – ACE-inhibitors – furosemide

Zdroje

1. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 2328–2334.

2. Kandzari DE, Rebeiz AG, Wang A et al. Contrast nephropathy: an evidence-based approach to prevention. Am J Cardiovasc Drugs 2003; 3: 395–405.

3. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79: 211–219.

4. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259–2264.

5. Cavusoglu E, Chhabra S, Marmur JD et al. The prevention of contrastinduced nephropathy in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol 2004; 52: 419–432.

6. Brendan J, Barrett MB, Parfey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379–386.

7. Soma VR, Cavusoglu E, Vidhun R et al. Contrast-associated nephropathy. Heart Dis 2002; 4: 372–379.

8. Oudemans-van Straaten HM Contrast nephropathy, pathophysiology and prevention. Int J Artif Organs 2004; 27: 1054–1065.

9. Johnson RJ, Feehalby J. Comprehensive Clinical Nephrology. London: Mosby 2003: 13–26, 215–216.

10. Katholi RE, Woods WT jr, Taylor GJ et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64–71.

11. Idée JM, Lancelot E, Pines E et al. Prophylaxis of iodinated contrast mediainduced nephropathy: a pharmacological point of view. Invest Radiol 2004; 39: 155–170.

12. Štípek S et al. Antioxidanty a volné radikály ve zdraví a nemoci. 1. ed. Praha: Grada Publishing 2000: 77–92.

13. Welch WJ, Tojo AB, Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 2000; 278: F769–F776.

14. Liang M, Knox FG. Production and functional roles of nitric oxide in the proximal tubule. Am J Physiol 2000; 278: 47.

15. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. Can Med Assoc J 2005; 172: 1461–1471.

16. Schück O, Tesař V, Teplan V. Klinická nefrologie. 1.ed. Praha: Medprint 1995: 266.

17. Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kid Int 2003; 64: 128–139.

18. Harwood SM, Yaqoob MM, Allen DA. Caspase and calpain function in cell death: Bridging the gap between apoptosis and necrosis. Ann Clin Biochem 2005; 42: 415–431.

19. Krusová D, Ševela K. Kontrastní látkou indukovaná nefropatie. Vnitř Lék 2006; 52(9): 805–811.

20. Chertow GM. Prevention of radiocontrast nephropathy: Back to basics. JAMA 2004; 291: 2376–2377.

21. Bader BD, Berger ED, Heede MB et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004; 62: 1–7.

22. The Royal Australian and New Zealand College of Radiologists: Guidelines for Metformin Hydrochloride and Intravascular Contrast, 2006; http://www.ranzcr.edu.au/collegegroups/reference/EBM/mhicm_guidel ines.cfm

23. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11: 177–182.

24. Haglund M, Hesselstrand R, Nyman U et al. Contrast-induced nephropathy after computer tomography. Hydration and adapted contrast media dosage for the best prophylaxis. Lakartidningen 2005; 102: 2864–2866 a 2869–2870.

25. McCullough PA, Soman SS. Contrast-induced nephropathy. Critical Care Clinics 2005; 21: 261–280.

26. Stříbrná J, Peregrin JH, Teplan V. Radiocontrast induced nephropathy. Prakt Lék 2003; 83: 270–272.

27. Bridges JM, Feldstein DA. Preventing contrast-induced nephropathy: a basic solution. WMJ 2005; 104: 9–10.

28. Asher I, Hammerman A, Sthoeger Z. New usage for an old drug: acetylcysteine for contrast-induced nephropathy. Harefuah 2005; 144: 642–646, 675.

29. Guru V, Fremes SE. The role of Nacetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 2004; 62: 77–83.

30. Birck R, Krzossok S, Markowetz F. Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003; 362: 598–603.

31. Shjalansky SJ, Vu T, Pate GE et al. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy 2005; 25: 1095–1103.

32. Spinazzi A, Pozzi Mucelli R Administration of iodinated contrast in patients with pre–existing renal failure. Radiol Med (Torino) 2004; 107: 88–97.

33. Briguiori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis 2003; 45: 493–503.

34. Gupta RK, Kapoor A, Tewari S et al. Captopril for Prevention of Contrast- Induced Nephropathy in Diabetic Patients: A Randomised Study. Indian Heart J 1999; 51: 521–526.

35. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416–1420.